PF-562271

Catalog No.S2890

Molecular Weight(MW): 507.49

PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.

Cited by 66 Publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(14):4552-4566

PubMed: 30979745 ( click the link to review the publication )

Sci Signal, 2019, 12(565)

PubMed: 30670633 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):738

PubMed: 31570694 ( click the link to review the publication )

J Biol Chem, 2019, 294(18):7221-7230

PubMed: 30846565 ( click the link to review the publication )

J Tissue Eng Regen Med, 2019, 13(4):625-636

PubMed: 30770650 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(6):1461-1469

PubMed: 31006845 ( click the link to review the publication )

Molecules, 2019, 24(10)

PubMed: 31109130 ( click the link to review the publication )

J Pharm Biomed Anal, 2019, 168:163-173

PubMed: 30807921 ( click the link to review the publication )

Mol Med Rep, 2019, 19(6):4753-4760

PubMed: 31059085 ( click the link to review the publication )

Zygote, 2019, 27(3):173-179

PubMed: 31171046 ( click the link to review the publication )

Cell Rep, 2018, 22(10):2784-2796

PubMed: 29514104 ( click the link to review the publication )

Oncogene, 2018, 37(23):3166-3182

PubMed: 29545604 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):848

PubMed: 30154481 ( click the link to review the publication )

Cancer Sci, 2018, 109(12):3783-3793

PubMed: 30281878 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(18):e008604

PubMed: 30371220 ( click the link to review the publication )

J Cell Sci, 2018, 131(10)

PubMed: 29678906 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:2190657

PubMed: 30275837 ( click the link to review the publication )

Int J Oncol, 2018, 53(4):1544-1556

PubMed: 30066854 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 10.1038/aps

PubMed: 29417941 ( click the link to review the publication )

Cell Cycle, 2018, 17(23):2577-2592

PubMed: 30488756 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2325-2333

PubMed: 30106432 ( click the link to review the publication )

Cancer Epidemiol Biomarkers Prev, 2018, 27(7):805-813

PubMed: 29654156 ( click the link to review the publication )
Sci Transl Med, 2017, 9(420)

PubMed: 29237758 ( click the link to review the publication )

Nat Commun, 2017, 8:14122

PubMed: 28098159 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1347-1356

PubMed: 28406574 ( click the link to review the publication )

FEBS J, 2017, 284(17):2856-2869

PubMed: 28665039 ( click the link to review the publication )

Sci Rep, 2017, 7(1):4032

PubMed: 28642549 ( click the link to review the publication )

Mol Carcinog, 2017, 56(12):2558-2565

PubMed: 28667800 ( click the link to review the publication )

Cancer Manag Res, 2017, 9:879-889

PubMed: 29276408 ( click the link to review the publication )

Cell Signal, 2017, 38:1-9

PubMed: 28647573 ( click the link to review the publication )

Oncol Rep, 2017, 38(1):63-70

PubMed: 28560386 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5817-5826

PubMed: 29263678 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2017, 2017:4535326

PubMed: 29234400 ( click the link to review the publication )

Mol Med Rep, 2017, 16(6):8937-8943

PubMed: 28990104 ( click the link to review the publication )

Oncotarget, 2017, 8(43):75102-75113

PubMed: 29088849 ( click the link to review the publication )

Biophys J, 2017, 113(7):1585-1598

PubMed: 28844472 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(2):168-80

PubMed: 26689676 ( click the link to review the publication )

Nat Commun, 2016, 7:10354

PubMed: 26838601 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(23):5851-5863

PubMed: 27220963 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):81

PubMed: 27495308 ( click the link to review the publication )

Oral Oncology, 2016, 10.1016/j.oraloncology.2016.05.010

PubMed: ( click the link to review the publication )

Sci Rep, 2016, 6:36214

PubMed: 27796369 ( click the link to review the publication )

J Biol Chem, 2016, 291(15):8140-9

PubMed: 26865633 ( click the link to review the publication )

Mol Pharmacol, 2016, 89(5):521-40

PubMed: 26895766 ( click the link to review the publication )
J Proteome Res, 2016, 15(12):4369-4386

PubMed: 27762562 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 71:62-71

PubMed: 26693891 ( click the link to review the publication )

Oncotarget, 2016, 7(30):48093-48106

PubMed: 27344177 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45186-45198

PubMed: 27286256 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(11):1412-21

PubMed: 26436690 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26274564 ( click the link to review the publication )

Oncogene, 2015, 34(40):5114-27

PubMed: 25639872 ( click the link to review the publication )

Cell Physiol Biochem, 2015, 37(2):515-26

PubMed: 26330161 ( click the link to review the publication )

J Biol Chem, 2015, 290(14):8677-92

PubMed: 25713079 ( click the link to review the publication )

Environ Toxicol Pharmacol, 2015, 39(1):114-24

PubMed: 25481308 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(20):E2595-601

PubMed: 25941386 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25755-69

PubMed: 26342198 ( click the link to review the publication )

Oncotarget, 2015, 6(3):1531-43

PubMed: 25605238 ( click the link to review the publication )

Environ Toxicol Pharm, 2014, 39(1):114-124

PubMed: 25481308 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Int J Clin Exp Pathol, 2013, 6(10):2082-91

PubMed: 24133586 ( click the link to review the publication )

Purity & Quality Control

Choose Selective FAK Inhibitors

Biological Activity

Description

Targets

FAK ^[1] (Cell-free assay)	PYK2 ^[1] (Cell-free assay)	CDK2/CyclinE ^[1] (Cell-free assay)	CDK3/CyclinE ^[1] (Cell-free assay)	CDK1/CyclinB ^[1] (Cell-free assay)	View More
1.5 nM	13 nM	30 nM	47 nM	58 nM	View More

In vitro

PF-562271 binds in the ATP-binding cleft of FAK, forming two of the three “canonical” H-bonds between the inhibitor and main-chain atoms in the kinase hinge region. PF-562271 is potent in an inducible cell-based assay measuring phospho-FAK with IC50 of 5 nM. PF-562271 (3.3 μM) results in G1 arrest of PC3-M cells. ^[1] PF-562271 (1 nM) blocks bFGF-stimulated blood vessel angiogenesis as performed in chicken chorioallantoic membrane assays. PF-262271 potently blocks blood vessel sprouting without detectable changes in vascular leakage. ^[2] PF-562271 (250 nM) results in complete inhibition of collective A431 cell invasion into collagen gels. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
MV-4-11	NUXxcWVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDZcGRKSzVyPUCuNlc3PiEQvF2=	MU\TRW5ITVJ?
SW982	MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUWyO\|dkUUN3ME2wMlMzQDJizszN	M4e1RnNCVkeHUh?=
KM12	M3zqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjjZZRKSzVyPUCuN\|g2PTdizszN	M2S3U3NCVkeHUh?=
COLO-205	M{[yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnkWZVyUUN3ME2wMlQ5PjV6IN88US=>	NHfJeoVUSU6JRWK=
COLO-829	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwN{WxO\|Yh\|ryP	M1[1RXNCVkeHUh?=
MG-63	NWjHVGJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjmXIlUUUN3ME2wMlgxPjN5IN88US=>	M{DSeXNCVkeHUh?=
IGROV-1	NGTzcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnld3BKSzVyPUCuPFExOzhizszN	M{TNdnNCVkeHUh?=
NCI-H650	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILoNoNKSzVyPUCuPFMyPTRizszN	M1;sXHNCVkeHUh?=
RT-112	NGjMPWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGq1c4JKSzVyPUCuPVg1PiEQvF2=	MX;TRW5ITVJ?
BCPAP	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLPSHlKSzVyPUGuNFEzQDhizszN	NFHZcIRUSU6JRWK=
ALL-PO	MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYThbZZ5UUN3ME2xMlAyPTh2IN88US=>	NH24S5lUSU6JRWK=
KYSE-270	M4LEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnFcHhKSzVyPUGuNFQ4OTRizszN	MkPwV2FPT0WU
8305C	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\4SpV2UUN3ME2xMlA6QTB2IN88US=>	M2rST3NCVkeHUh?=
NCI-H810	NXzWe5BnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2KyemlEPTB;MT6xNFc4PiEQvF2=	M3;KU3NCVkeHUh?=
CAL-33	M1L5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXzcZh4UUN3ME2xMlEzQTN6IN88US=>	M1jtSXNCVkeHUh?=
AN3-CA	M1fFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfoTWM2OD1zLkKxPFY4KM7:TR?=	M1zxXnNCVkeHUh?=
NKM-1	NFfSe2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH[yfG9KSzVyPUGuNlc2ODZizszN	MUPTRW5ITVJ?
BPH-1	NEjYOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTFwMki3OlYh\|ryP	NULuTFE2W0GQR1XS
MES-SA	MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTFwM{C2PFIh\|ryP	M1f1SXNCVkeHUh?=
CAL-62	NGHrcJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPXTWM2OD1zLkOxPVA6KM7:TR?=	MXPTRW5ITVJ?
Detroit562	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzGTWM2OD1zLkO1NlIzKM7:TR?=	MWrTRW5ITVJ?
KYSE-150	NVzRZm1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvYZXhKSzVyPUGuN\|UzOzZizszN	NHnRU2NUSU6JRWK=
SK-UT-1	M{[yNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXYeWRKSzVyPUGuOFQ3PDdizszN	NHS1TJNUSU6JRWK=
HUTU-80	MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTFwNES4PFYh\|ryP	NVfLSWhzW0GQR1XS
SIG-M5	NFjtN5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfDTGtiUUN3ME2xMlQ5Ozh5IN88US=>	M2C4NXNCVkeHUh?=
AGS	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3z1SGlEPTB;MT61NlEzPCEQvF2=	M125PHNCVkeHUh?=
ST486	M{XiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGO0S2hKSzVyPUGuOVMzPzhizszN	M2KwUnNCVkeHUh?=
HSC-2	NWntXpJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;WTWM2OD1zLkWzPVUh\|ryP	MnHqV2FPT0WU
LCLC-103H	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTFwNUW4NVgh\|ryP	NEntdW1USU6JRWK=
BC-1	NI\sXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmW5TWM2OD1zLk[xOlY1KM7:TR?=	MnX0V2FPT0WU
CGTH-W-1	NUXJXVZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTFwNkG2O\|kh\|ryP	NIrEd5NUSU6JRWK=
MZ1-PC	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37vSGlEPTB;MT62NlMyOiEQvF2=	NH7BXI9USU6JRWK=
SW1710	NVvpbIZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLBTWM2OD1zLk[yOlI5KM7:TR?=	MWfTRW5ITVJ?
EW-13	M4XXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7hO\|BKSzVyPUGuOlM1PjZizszN	MnfkV2FPT0WU
TE-11	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPjT\|JiUUN3ME2xMlY{PTJ{IN88US=>	NYHhe2JYW0GQR1XS
BHY	NFe2OlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHSwcJdKSzVyPUGuOlU3PjNizszN	MlzwV2FPT0WU
ML-2	M1nRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTFwNk[4NFIh\|ryP	M{nXSHNCVkeHUh?=
MEL-JUSO	M2HWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;lTWM2OD1zLkeyPFkyKM7:TR?=	M4i0dHNCVkeHUh?=
U251	NUX6SW9iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mli2TWM2OD1zLke0NFMyKM7:TR?=	M1fXd3NCVkeHUh?=
MHH-ES-1	NWLM[WMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH:0XXpKSzVyPUGuO\|k2PjhizszN	Ml:0V2FPT0WU
CAL-85-1	NHzST3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zkV2lEPTB;MT64NFQ6KM7:TR?=	MkG3V2FPT0WU
D-336MG	M{DzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjaR4lKSzVyPUGuPFU3OTRizszN	M2jONnNCVkeHUh?=
VA-ES-BJ	Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rRW2lEPTB;MT65NFMyPSEQvF2=	MYjTRW5ITVJ?
MDA-MB-468	NWfkXlFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\STmlEPTB;MT65NVI4OiEQvF2=	MnzwV2FPT0WU
MEL-HO	M{f4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYW1[pRbUUN3ME2xMlk4QTl\|IN88US=>	NU\xTVlQW0GQR1XS
SW954	NGK4[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjIb45KSzVyPUKuNFAyPTFizszN	NILQW41USU6JRWK=
LB831-BLC	Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HSRWlEPTB;Mj6wNFk5QCEQvF2=	NV3ZV\|dqW0GQR1XS
EW-16	M2fGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTJwMEO5PFMh\|ryP	NHjsPGtUSU6JRWK=
NCI-H460	NFfycHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LBVmlEPTB;Mj6wOFg{QSEQvF2=	MnHvV2FPT0WU
CHP-212	NWD0dYJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fRcWlEPTB;Mj6wPVU{QSEQvF2=	MmTCV2FPT0WU
MHH-NB-11	NV;EXGNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV[xTZhwUUN3ME2yMlEzQDF6IN88US=>	MY\TRW5ITVJ?
DU-4475	NFLLO41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTJwMUS3OVkh\|ryP	M4HGNXNCVkeHUh?=
ABC-1	NYf5Om5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDxTWM2OD1{LkK1NVk3KM7:TR?=	MnLIV2FPT0WU
LOUCY	M17FdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\mdGVPUUN3ME2yMlI3OTJ6IN88US=>	MkW4V2FPT0WU
LC-2-ad	M{W0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTJwMk[5OlYh\|ryP	M33iNHNCVkeHUh?=
ETK-1	M1rqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnXTJdKSzVyPUKuNlg1PiEQvF2=	NGPTXWNUSU6JRWK=
KYSE-180	M4myc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTSNGhKSzVyPUKuNlg5PzRizszN	NWq4OpZ{W0GQR1XS
HOP-92	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHTTWM2OD1{LkOwOlc{KM7:TR?=	MlPJV2FPT0WU
RCC10RGB	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjWT3JKSzVyPUKuN\|I2ODdizszN	MYTTRW5ITVJ?
KASUMI-1	NVvmbXpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEe0[GhKSzVyPUKuN\|I5QCEQvF2=	NIWzTFNUSU6JRWK=
ACN	NWHVS4hyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYL4e\|FCUUN3ME2yMlM1PzR3IN88US=>	Mmf6V2FPT0WU
BxPC-3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zKVmlEPTB;Mj6zOVQ{PiEQvF2=	MnyxV2FPT0WU
MONO-MAC-6	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzDdZZKSzVyPUKuOFEzPDhizszN	M17WZ3NCVkeHUh?=
CAL-39	NWC0SJFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvsNlZPUUN3ME2yMlQyPjJ6IN88US=>	MWHTRW5ITVJ?
CMK	M3rpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLUTWM2OD1{LkSxO\|k2KM7:TR?=	M3fEcXNCVkeHUh?=
MFE-296	MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\PPWtyUUN3ME2yMlQ4Pzl{IN88US=>	MmiyV2FPT0WU
DU-145	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofTTWM2OD1{LkS5NVE5KM7:TR?=	MYnTRW5ITVJ?
MDA-MB-231	NXW2XHBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2K2NWlEPTB;Mj60PVU4OiEQvF2=	MWnTRW5ITVJ?
EFO-27	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHK5PG5KSzVyPUKuOVE5QDhizszN	NYf1bGFSW0GQR1XS
SNU-387	MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTJwNUK4NkDPxE1?	Ml\hV2FPT0WU
KYSE-410	NFnZN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLlcFFxUUN3ME2yMlU3PTF5IN88US=>	NYfkeJViW0GQR1XS
NCCIT	M1fkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LHUGlEPTB;Mj61O\|I1KM7:TR?=	MX3TRW5ITVJ?
LXF-289	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTJwNUiyO\|Mh\|ryP	NV35b2M4W0GQR1XS
HMV-II	NXnZV3VHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETmbnRKSzVyPUKuOVg6QTdizszN	MkWzV2FPT0WU
MOLT-4	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTJwNkC3NVIh\|ryP	NHnSOHlUSU6JRWK=
KOSC-2	M{L4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTJwNkO4O\|kh\|ryP	M3;RcHNCVkeHUh?=
TUR	NEfxT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\0TWM2OD1{Lk[1N\|Y6KM7:TR?=	NIHN[29USU6JRWK=
NCI-H2087	MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkf0TWM2OD1{LkexOlQ3KM7:TR?=	MlXFV2FPT0WU
SCC-15	M4jpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\BeoxUUUN3ME2yMlc2OjV{IN88US=>	NYK4eJdzW0GQR1XS
HSC-4	M3W3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrPSIo6UUN3ME2yMlc5Ozh7IN88US=>	NUnEeYk3W0GQR1XS
G-402	M3GyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTJwOEG0OFch\|ryP	M2Hje3NCVkeHUh?=
GP5d	M2\wUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkL2TWM2OD1{LkizPFI4KM7:TR?=	MWnTRW5ITVJ?
IGR-1	NFnXbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILsb5FKSzVyPUKuPFM6QDdizszN	MkHaV2FPT0WU
SK-PN-DW	NEfZUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjBSJdPUUN3ME2yMlg3OjB2IN88US=>	M3nMSXNCVkeHUh?=
OPM-2	MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLkTWM2OD1{Lki5PVc5KM7:TR?=	NFzhT3BUSU6JRWK=
5637	M2GxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTJwOUK0N\|kh\|ryP	NGf3bYZUSU6JRWK=
NCI-H2030	M{TtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjXeJpKSzVyPUKuPVgxOjlizszN	MUnTRW5ITVJ?
SK-LU-1	NXHyWoZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljqTWM2OD1{Lkm4N\|M1KM7:TR?=	MmPUV2FPT0WU
EW-18	NFv2bINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13COmlEPTB;Mz6wOVMzKM7:TR?=	MUHTRW5ITVJ?
786-0	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTNwMEW3PFQh\|ryP	NWDmb\|ZqW0GQR1XS
NCI-H1963	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTNwMEi4NlUh\|ryP	M1\sbXNCVkeHUh?=
A2780	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVf6dYpWUUN3ME2zMlExOzRzIN88US=>	M3q4R3NCVkeHUh?=
NCI-H526	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTNwMUO5OlEh\|ryP	M3f3SXNCVkeHUh?=
BHT-101	NY\iTJNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfITWM2OD1\|LkG1O\|k5KM7:TR?=	MYLTRW5ITVJ?
RPMI-7951	NFraW\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDYdmlUUUN3ME2zMlIxOTN5IN88US=>	NFL0eodUSU6JRWK=
HL-60	NFrYTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPnTWM2OD1\|LkKxNVQh\|ryP	MoryV2FPT0WU
CTV-1	MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfJUpFVUUN3ME2zMlI2Ozd5IN88US=>	M2niTXNCVkeHUh?=
IST-SL1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUewOWp1UUN3ME2zMlI6PDZ3IN88US=>	MUnTRW5ITVJ?
G-401	NFTkcYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTNwMkm4NFgh\|ryP	MWTTRW5ITVJ?
OVCAR-5	M2\hXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfhTWM2OD1\|LkO2N\|UzKM7:TR?=	NUDZfmZWW0GQR1XS
EW-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHNSmpGUUN3ME2zMlQxPTR2IN88US=>	M{LiZnNCVkeHUh?=
H4	NGPBWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfxUm9KSzVyPUOuOFc2PjlizszN	NVrrNpZ1W0GQR1XS
EM-2	NX7McIk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37jZ2lEPTB;Mz60PFY4PCEQvF2=	Mmn4V2FPT0WU
RS4-11	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\3R2lEPTB;Mz60PFcyPSEQvF2=	NVHMfmZxW0GQR1XS
NOMO-1	NVjtd2MxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLtUWhKSzVyPUOuOFkzODRizszN	M2LT[nNCVkeHUh?=
HCT-116	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjI[ndZUUN3ME2zMlUxPzFzIN88US=>	MkPMV2FPT0WU
CAL-120	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTkc\|hKSzVyPUOuOVc{PSEQvF2=	MYDTRW5ITVJ?
CAL-51	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrmU3ZrUUN3ME2zMlU4PjF{IN88US=>	NInuV4VUSU6JRWK=
RVH-421	M1Hre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3uxUmlEPTB;Mz62NFMyOSEQvF2=	MnPVV2FPT0WU
NCI-H2081	NEjKcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTNwNkWyPFgh\|ryP	NYrPXnZbW0GQR1XS
SBC-5	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVSxRlY4UUN3ME2zMlY4QDh{IN88US=>	M3zkenNCVkeHUh?=
RL95-2	NGPjcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI[wRWFKSzVyPUOuO\|E5PjRizszN	M1TpRXNCVkeHUh?=
SW872	M1zaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nmcmlEPTB;Mz63Olk2QCEQvF2=	NHHBWFlUSU6JRWK=
VM-CUB-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nQ[GlEPTB;Mz63O\|UyKM7:TR?=	MorWV2FPT0WU
SUP-T1	MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{joTmlEPTB;Mz63PFMzKM7:TR?=	MYjTRW5ITVJ?
697	MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TpZmlEPTB;Mz64NVY2PyEQvF2=	NULnfnBzW0GQR1XS
DBTRG-05MG	M2PLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jEVGlEPTB;Mz64NVY4PiEQvF2=	NEPrb3ZUSU6JRWK=
TE-441-T	NW\iUY5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTNwOEK5N{DPxE1?	MoD3V2FPT0WU
A204	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTFTWM2OD1\|LkmwPVU3KM7:TR?=	NX7re2Q4W0GQR1XS
HCC2998	M1jMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHNWo1{UUN3ME2zMlk1QDR\|IN88US=>	MUTTRW5ITVJ?
SCC-4	NH;IdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DneGlEPTB;Mz65OVc5OiEQvF2=	MnXmV2FPT0WU
ACHN	NWLhemxZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTRwMEKzO{DPxE1?	M3LVV3NCVkeHUh?=
NB1	MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUKyWlZzUUN3ME20MlA3PjR2IN88US=>	NVjGWlgyW0GQR1XS
PANC-08-13	NGjROoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnJSJR1UUN3ME20MlA4PzNizszN	MnW2V2FPT0WU
A4-Fuk	MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGL2VJFKSzVyPUSuNFc5PjFizszN	M1P0[3NCVkeHUh?=
NCI-H747	NHz0SndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXlTWM2OD12LkC4Olc1KM7:TR?=	M2XhOXNCVkeHUh?=
G-361	NVW1d4lXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTRwMEmwOkDPxE1?	MmrCV2FPT0WU
NCI-H292	NHXm[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofWTWM2OD12LkC5OFI6KM7:TR?=	MYjTRW5ITVJ?
HGC-27	MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonoTWM2OD12LkC5OVQ6KM7:TR?=	NGjQUndUSU6JRWK=
ATN-1	NUfaNGdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;o[ZBCUUN3ME20MlExPzd5IN88US=>	MXnTRW5ITVJ?
RPMI-2650	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;OWJZvUUN3ME20MlEzQTd3IN88US=>	MkDoV2FPT0WU
SIMA	NEnKelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmK4TWM2OD12LkG0OEDPxE1?	NHX6dHFUSU6JRWK=
CA46	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moi4TWM2OD12LkG2NVA1KM7:TR?=	NXjZd3hCW0GQR1XS
CHL-1	NV;yZVV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrhTWM2OD12LkG4PVYyKM7:TR?=	NHHVe3NUSU6JRWK=
TE-10	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;KOWRKSzVyPUSuNlI5QDdizszN	NE\6To1USU6JRWK=
NCI-H1734	NXrsOlBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLa[pJKSzVyPUSuNlY3QTVizszN	MkXRV2FPT0WU
DV-90	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnKxTWM2OD12LkK5N\|k4KM7:TR?=	MVzTRW5ITVJ?
MOLT-16	MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTRwM{GwNVYh\|ryP	NV3EeI5WW0GQR1XS
HuCCT1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTRwM{O3NlMh\|ryP	MVPTRW5ITVJ?
A3-KAW	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTRwM{W1OVIh\|ryP	MmH2V2FPT0WU
HOS	NGrYcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;NZWlEPTB;ND6zPFU3PyEQvF2=	MXTTRW5ITVJ?
KS-1	Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTRwNEK0OVkh\|ryP	MoPRV2FPT0WU
SNU-423	NEnWdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4ftRWlEPTB;ND60NlY5PSEQvF2=	MonsV2FPT0WU
BC-3	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjhcGJKSzVyPUSuOFM1PzdizszN	MWTTRW5ITVJ?
SCC-9	NUjLNo5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjXdlBDUUN3ME20MlQ1Ojl7IN88US=>	Mme4V2FPT0WU
C8166	MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGW0b4JKSzVyPUSuOFc4PTNizszN	MVvTRW5ITVJ?
NCI-H358	NVTnPVU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LxPWlEPTB;ND60PFU{OiEQvF2=	NWn5WXZKW0GQR1XS
GT3TKB	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LGO2lEPTB;ND60PFgzOiEQvF2=	M2ntVnNCVkeHUh?=
NCI-SNU-1	NI[1eZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mor0TWM2OD12LkS5O\|AyKM7:TR?=	MYHTRW5ITVJ?
Ca9-22	NWPDN3dtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Lpb2lEPTB;ND61OVUyPiEQvF2=	M2ruN3NCVkeHUh?=
L-363	NEPEU\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTRwNUW5PVYh\|ryP	MmXFV2FPT0WU
Calu-1	MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXY[GoyUUN3ME20MlU5PzB5IN88US=>	M2T2SHNCVkeHUh?=
OE19	M1\3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2O0R2lEPTB;ND62N\|E1PSEQvF2=	NG[ydG5USU6JRWK=
COR-L23	Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVv1coFrUUN3ME20MlY4OjhizszN	NXrBcnl[W0GQR1XS
A431	NYTzbI1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPGTWM2OD12Lk[4NlI5KM7:TR?=	MUXTRW5ITVJ?
MKN1	M4\3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTRwN{C2OlUh\|ryP	Ml3sV2FPT0WU
SH-4	M1vBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnxUmg2UUN3ME20MlczPjN\|IN88US=>	NE\lTVZUSU6JRWK=
SNB75	MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLXV3dKSzVyPUSuO\|Q3PiEQvF2=	MXHTRW5ITVJ?
SW780	MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDsTW1KSzVyPUSuO\|Y5PDlizszN	M2XxNHNCVkeHUh?=
GOTO	MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlKxTWM2OD12Lke5Nlk{KM7:TR?=	M{jyU3NCVkeHUh?=
U-266	NXfzUWZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;2Z4ZKSzVyPUSuPVQ6OTlizszN	NFroTFZUSU6JRWK=
KURAMOCHI	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTVwMEK4N\|Qh\|ryP	NEXwdJJUSU6JRWK=
NMC-G1	MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrPcWlKSzVyPUWuNFkyOzlizszN	MXrTRW5ITVJ?
COLO-684	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTVwMkWzO\|Eh\|ryP	MXTTRW5ITVJ?
NTERA-S-cl-D1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLXeZBKSzVyPUWuNlkzOThizszN	NY[3WYYzW0GQR1XS
RD	NXLTV5BIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml21TWM2OD13LkK5O\|cyKM7:TR?=	MmfsV2FPT0WU
A2058	MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnr0TWM2OD13LkOwOFM5KM7:TR?=	M{XZRnNCVkeHUh?=
NCI-H2009	NXPSfXNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTVwM{C1N\|gh\|ryP	NVj1R2pnW0GQR1XS
8-MG-BA	M3TwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\LN2lEPTB;NT6zO\|A4PyEQvF2=	NYTwcWZXW0GQR1XS
LC4-1	Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTVwM{mzNFMh\|ryP	M2\URnNCVkeHUh?=
A101D	NV7Ie3NCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVP4VJNlUUN3ME21MlM6Pjh7IN88US=>	MXHTRW5ITVJ?
ES8	MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTVwNEG0NFkh\|ryP	NEPBUnFUSU6JRWK=
SF126	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13YRWlEPTB;NT60NVQ3PSEQvF2=	MVzTRW5ITVJ?
GDM-1	MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTVwNEG3PFEh\|ryP	NU\V[FhiW0GQR1XS
TE-6	NULDSIo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDsSVlKSzVyPUWuOFQ2PjlizszN	MYjTRW5ITVJ?
SR	NX7tRo9[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPtfmNKSzVyPUWuOVM3PDVizszN	NFvtNmpUSU6JRWK=
HOP-62	NV;MXFBJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTVwNU[4PFch\|ryP	NWThToM1W0GQR1XS
HCC2157	M{TrTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rsWWlEPTB;NT61Olg6PiEQvF2=	MU\TRW5ITVJ?
TE-15	NE\3VoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTtR3BKSzVyPUWuOVc4PzlizszN	M1HyRXNCVkeHUh?=
BFTC-905	MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlr2TWM2OD13Lk[wOFIyKM7:TR?=	NV\SVVlHW0GQR1XS
TE-9	MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjCR\|RKSzVyPUWuOlE4QDhizszN	M{XvNnNCVkeHUh?=
647-V	NF[3TIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLpfYNKSzVyPUWuOlIxPDJizszN	MYjTRW5ITVJ?
KG-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTVwN{SwNFUh\|ryP	NUK2e3VJW0GQR1XS
KYSE-510	MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlz6TWM2OD13Lke5OVgyKM7:TR?=	MXzTRW5ITVJ?
SK-MES-1	M3HE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PDZmlEPTB;NT64OVg6OSEQvF2=	NXHLepNPW0GQR1XS
OVCAR-3	NIjyZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEj1SZZKSzVyPUWuPFgzODZizszN	MoO0V2FPT0WU
LB1047-RCC	Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml[4TWM2OD13LkmwNVQ5KM7:TR?=	NEDUNoZUSU6JRWK=
HEL	NFS4UWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjXW2xKSzVyPU[uNFIyQDhizszN	MVXTRW5ITVJ?
KARPAS-45	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPnO5R{UUN3ME22MlA{Pzh5IN88US=>	NIfzUWVUSU6JRWK=
NCI-H1304	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TzVWlEPTB;Nj6xNlQ6PyEQvF2=	NUnYOWpMW0GQR1XS
PC-3	NGexV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTZwMUOwO\|Ih\|ryP	NIXrR4VUSU6JRWK=
Calu-3	NYLLe3h1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTZwMUS2PFkh\|ryP	NUPucWZoW0GQR1XS
NCI-H1648	MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4S5VWlEPTB;Nj6xOVE3KM7:TR?=	NVSyW3lUW0GQR1XS
HSC-3	M1ThfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnS3TWM2OD14LkG3N\|k3KM7:TR?=	MXHTRW5ITVJ?
COLO-824	M2TZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;5TWM2OD14LkK3PFY5KM7:TR?=	MXvTRW5ITVJ?
COLO-680N	M1\SOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jHN2lEPTB;Nj6zO\|Y{QCEQvF2=	M3fpb3NCVkeHUh?=
SK-NEP-1	MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTZwNECzOkDPxE1?	NHj3W2FUSU6JRWK=
SCC-25	M{Hy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDNd3hKSzVyPU[uOFI1QTNizszN	MWrTRW5ITVJ?
SF295	MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfVSnVMUUN3ME22MlQ1QThizszN	M1OwW3NCVkeHUh?=
no-10	MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHKVFBIUUN3ME22MlQ4QDRizszN	M2jzNXNCVkeHUh?=
NCI-H838	M{S2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;uTWM2OD14LkWxO\|A{KM7:TR?=	M3y5SXNCVkeHUh?=
M059J	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjpTWM2OD14LkW1OlI2KM7:TR?=	NHPWS2ZUSU6JRWK=
Calu-6	NXe5elJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MliwTWM2OD14Lk[1OFM2KM7:TR?=	MXjTRW5ITVJ?
TE-12	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTZwN{KzO\|ch\|ryP	MnW0V2FPT0WU
639-V	MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXDSnVKSzVyPU[uO\|UyOjdizszN	MVrTRW5ITVJ?
ESS-1	NELDRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTsTWM2OD14Lke2NFczKM7:TR?=	Mn:5V2FPT0WU
C-4-II	MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkm5TWM2OD14LkizNVE4KM7:TR?=	NWXY[ox4W0GQR1XS
23132-87	NVHr[YpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTZwOUC5NFEh\|ryP	MkOwV2FPT0WU
MEG-01	NWjZTmEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfVZVE6UUN3ME22Mlk{PTR4IN88US=>	MkHPV2FPT0WU
GI-1	NX32Z3Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTZwOUSzOFgh\|ryP	MX;TRW5ITVJ?
NCI-H2347	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfkeHNUUUN3ME22Mlk1PzF3IN88US=>	MkTHV2FPT0WU
MS-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPSTWM2OD14Lkm1NVkzKM7:TR?=	MWXTRW5ITVJ?
SK-MEL-30	NV\jNm12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTZwOU[zNVUh\|ryP	MXfTRW5ITVJ?
YKG-1	NID0PJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTdwMEK2O\|gh\|ryP	Ml7oV2FPT0WU
HT-3	NIDvWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfVRXRKSzVyPUeuNFM1QSEQvF2=	MVXTRW5ITVJ?
NCI-H2126	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTdwMEm3PVEh\|ryP	NVexSXJXW0GQR1XS
GI-ME-N	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\ETWM2OD15LkG2PVA3KM7:TR?=	MWLTRW5ITVJ?
LB771-HNC	NFPpbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTdwMUiwN\|gh\|ryP	MVPTRW5ITVJ?
LCLC-97TM1	Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHznVIpKSzVyPUeuNlEzPzNizszN	MmD3V2FPT0WU
HO-1-N-1	M4TPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nYTmlEPTB;Nz6yOFAzPCEQvF2=	MlP6V2FPT0WU
HCC1143	M2\p[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1f1VmlEPTB;Nz6zO\|g6QCEQvF2=	MmLSV2FPT0WU
HuO9	NVzESlNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXtZ4RKSzVyPUeuOFg4QTRizszN	NH:yPHJUSU6JRWK=
IST-SL2	NWfMe2RPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHuwe5lKSzVyPUeuOVIzPzJizszN	Ml72V2FPT0WU
MLMA	M4\jeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnPV3lnUUN3ME23MlU1Pjh7IN88US=>	M173fHNCVkeHUh?=
22RV1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXwZ\|VDUUN3ME23MlY4QTd3IN88US=>	NH3FeFNUSU6JRWK=
ONS-76	Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTdwNkm0NVYh\|ryP	MXzTRW5ITVJ?
ECC12	NH\kRYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NET1e2hKSzVyPUeuO\|I6ODFizszN	M{HKV3NCVkeHUh?=
HT-1080	Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTdwN{i1OVUh\|ryP	M3fkPHNCVkeHUh?=
SF268	M37UNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnGTWM2OD15LkizOVYh\|ryP	M3Pye3NCVkeHUh?=
COLO-800	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXKweFg6UUN3ME23MlkxPjh3IN88US=>	NGTheI9USU6JRWK=
BB30-HNC	NYmzSJozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rrdmlEPTB;Nz65OFU2OyEQvF2=	NFzZOWJUSU6JRWK=
CAKI-1	NHPXXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFqySZFKSzVyPUiuNFY2OjFizszN	NEW4VY9USU6JRWK=
GCIY	NIPOb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fGRWlEPTB;OD6yN\|cyOyEQvF2=	NU[1[m1lW0GQR1XS
MKN28	M4G4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPnTWM2OD16LkK0OVk5KM7:TR?=	M3yyU3NCVkeHUh?=
IPC-298	Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnnUI9KSzVyPUiuNlc4ODlizszN	M{K1enNCVkeHUh?=
NCI-H1650	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHVTG9KUUN3ME24MlI6OTh3IN88US=>	MVfTRW5ITVJ?
KP-N-YS	MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDMR2xKSzVyPUiuNlk{ODhizszN	M3PkVnNCVkeHUh?=
J82	NYn4fVdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXxO2ZKSzVyPUiuN\|QyOjRizszN	MkfHV2FPT0WU
SK-HEP-1	NI\pXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TETGlEPTB;OD6zOVczOyEQvF2=	NF;admRUSU6JRWK=
PANC-03-27	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7x[oxKSzVyPUiuN\|Y6OiEQvF2=	NGXQNIJUSU6JRWK=
KP-4	M2nCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvHTWM2OD16LkSxPFU{KM7:TR?=	NES1eIxUSU6JRWK=
RERF-LC-MS	NE\Nb\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XySWlEPTB;OD60PFU6PSEQvF2=	MWTTRW5ITVJ?
C-33-A	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7VTXhKSzVyPUiuOlE2OjlizszN	MXvTRW5ITVJ?
PA-1	MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRThwNk[2PVQh\|ryP	Mn\RV2FPT0WU
TE-5	NY[1SG84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX65NmNxUUN3ME24MlcxOjl4IN88US=>	M1S3SXNCVkeHUh?=
MHH-PREB-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFG1[YFKSzVyPUiuO\|MyODdizszN	MmDJV2FPT0WU
C3A	NYTxcHB2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PyXmlEPTB;OD63OlU3OSEQvF2=	NFr0d2tUSU6JRWK=
SK-OV-3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rjXGlEPTB;OD63PVc4OiEQvF2=	NWn4b\|RGW0GQR1XS
AM-38	Mk\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRThwOEC0N\|kh\|ryP	MVPTRW5ITVJ?
LoVo	NUP4XZQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRThwOUW1OlYh\|ryP	M2DVN3NCVkeHUh?=
MKN45	NUTEW2ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M361cmlEPTB;OD65OlA3OyEQvF2=	M3X4VnNCVkeHUh?=
NH-12	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI[4WIxKSzVyPUmuNFI2PDJizszN	MkTJV2FPT0WU
CAMA-1	NHnIVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTEUJVKSzVyPUmuNFYxOTJizszN	MXHTRW5ITVJ?
HT-29	NXS3eWNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjlTWM2OD17LkGyN\|c{KM7:TR?=	NYLxVGZbW0GQR1XS
DMS-273	MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;qXmlEPTB;OT6xNlUh\|ryP	M{LaZ3NCVkeHUh?=
NCI-H719	M17Mdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTlwMUizPVEh\|ryP	NUTzNG43W0GQR1XS
SF539	MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLjNG5KSzVyPUmuNlExQThizszN	NH7ifXRUSU6JRWK=
Daoy	M3Sxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTlwMkSxOFMh\|ryP	NVu2dnhIW0GQR1XS
HCC70	Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmD6TWM2OD17LkK3N\|A6KM7:TR?=	M1PYSXNCVkeHUh?=
MFH-ino	MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTlwMkmwNFch\|ryP	M4LneHNCVkeHUh?=
UACC-62	NVTK[3FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rKUGlEPTB;OT6zO\|I6PyEQvF2=	NHrMSm1USU6JRWK=
C2BBe1	MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTlwM{m2OVIh\|ryP	M3nzWnNCVkeHUh?=
KNS-42	M3fP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfVTWM2OD17LkSzOFA4KM7:TR?=	M3H0RXNCVkeHUh?=
SK-LMS-1	NY\VfZRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorSTWM2OD17Lke1OVM2KM7:TR?=	MkDvV2FPT0WU
SK-CO-1	Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTZZZJKSzVyPUmuO\|YzOzVizszN	NEK1bHpUSU6JRWK=
SN12C	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M331e2lEPTB;OT63OlgxPiEQvF2=	M1nMSXNCVkeHUh?=
HTC-C3	NULve2pxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7lN2NsUUN3ME25Mlc4QTh2IN88US=>	NETYRY1USU6JRWK=
OVCAR-4	M2DtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\wZ2lEPTB;OT64OFgzQCEQvF2=	NWHI[4ZQW0GQR1XS
CHP-126	NIPCbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7YS2NKSzVyPUmuPVMzQSEQvF2=	M1;rUXNCVkeHUh?=
NCI-H716	NEHDTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPYTWM2OD17LkmzN\|IzKM7:TR?=	NELUN45USU6JRWK=
U-698-M	NHfvTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTlwOUm3JO69VQ>?	MYjTRW5ITVJ?
EFO-21	NUXXPGhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTFyLkCwPVMh\|ryP	NX\mdW15W0GQR1XS
RXF393	NUTHUlI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlGzTWM2OD1zMD6xN\|kzKM7:TR?=	M33qR3NCVkeHUh?=
ChaGo-K-1	Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrHTWM2OD1zMD6xO\|c3KM7:TR?=	MnT0V2FPT0WU
SJRH30	MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVy0N\|NJUUN3ME2xNE4yQDR2IN88US=>	NHjwbnJUSU6JRWK=
LU-65	M1m0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;SdYVtUUN3ME2xNE4zQTR\|IN88US=>	MnrlV2FPT0WU
OS-RC-2	NHL2WJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7MUmdwUUN3ME2xNE4{OjJ5IN88US=>	M33jUnNCVkeHUh?=
YT	NGm1[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XWd2lEPTB;MUCuOFAxOSEQvF2=	M1L5WHNCVkeHUh?=
COLO-679	NUHsN2d2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGO0ZnhKSzVyPUGwMlQzQDVizszN	M2rNOHNCVkeHUh?=
CAS-1	M{nxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEL3XZVKSzVyPUGwMlQ3ODhizszN	NHvJ[IVUSU6JRWK=
NCI-H2052	MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTFyLkWxNFUh\|ryP	MWfTRW5ITVJ?
NCI-H2452	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXVTWM2OD1zMD62NVgyKM7:TR?=	NI[1RZRUSU6JRWK=
SW13	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M164SWlEPTB;MUCuOlM4PCEQvF2=	MYTTRW5ITVJ?
HuP-T4	NFzmeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTFyLkewOlgh\|ryP	NEjpVphUSU6JRWK=
UMC-11	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DBOmlEPTB;MUCuPVM4OyEQvF2=	MXvTRW5ITVJ?
EGI-1	NIrUZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fnbWlEPTB;MUCuPVQ2PSEQvF2=	MYLTRW5ITVJ?
JiyoyeP-2003	NX\KU\|lxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTZV3ptUUN3ME2xNU4xQDl{IN88US=>	NELK[XVUSU6JRWK=
J-RT3-T3-5	M3;2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPkfZgzUUN3ME2xNU4yOjB7IN88US=>	NUDvTFdwW0GQR1XS
DoTc2-4510	Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLhTWM2OD1zMT6xN\|g6KM7:TR?=	NXnPOFF4W0GQR1XS
HLE	NUjw[4d3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rJbWlEPTB;MUGuNlEyQSEQvF2=	NH7BVY9USU6JRWK=
SW626	Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\sVowxUUN3ME2xNU4zQDh7IN88US=>	NUDyW5dkW0GQR1XS
COR-L105	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPNTXhKSzVyPUGxMlMzOzdizszN	MoCzV2FPT0WU
ES6	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnkUI1PUUN3ME2xNU42PzZizszN	NUXXRYNLW0GQR1XS
SNU-449	NHjTSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTNS4x[UUN3ME2xNU43ODd{IN88US=>	M{Pz[nNCVkeHUh?=
GR-ST	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLGTWM2OD1zMT62NVgyKM7:TR?=	M3rqTHNCVkeHUh?=
BL-41	NFLNb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rDW2lEPTB;MUGuO\|E4OyEQvF2=	NWXLWJdXW0GQR1XS
GB-1	NYfpSZh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUD1NFBtUUN3ME2xNU44PjF7IN88US=>	NYXpTVFxW0GQR1XS
COLO-320-HSR	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3MTWpuUUN3ME2xNU45PTF7IN88US=>	NY\SdpRSW0GQR1XS
L-540	NES4Ro5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{L2VmlEPTB;MUGuPFk6KM7:TR?=	M1m5dXNCVkeHUh?=
NCI-H69	M2\J[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3nTWM2OD1zMj6wNVM6KM7:TR?=	MXHTRW5ITVJ?
769-P	NFG5S29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\6O5JKSzVyPUGyMlAyQSEQvF2=	NEDUOGJUSU6JRWK=
A172	NU\ScG5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTF{LkGyNFch\|ryP	NYH6TGx{W0GQR1XS
CAL-27	NF3GfZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;6eWlEPTB;MUKuNVM3QSEQvF2=	NHr0WVRUSU6JRWK=
NCI-H1437	NXXLNJF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVf2dlRrUUN3ME2xNk4yPDR5IN88US=>	NHG0dItUSU6JRWK=
REH	M2\rfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTZTWM2OD1zMj6xOVc{KM7:TR?=	NHrkS3VUSU6JRWK=
KINGS-1	MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTF{LkO0NlEh\|ryP	NXf2cFZUW0GQR1XS
NCI-H1792	M2\0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFf4RlRKSzVyPUGyMlM5PTFizszN	MWLTRW5ITVJ?
SK-MM-2	Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPIZndoUUN3ME2xNk41ODh5IN88US=>	M2TSPHNCVkeHUh?=
8505C	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjOV4tKSzVyPUGyMlYyOiEQvF2=	NFTFWHNUSU6JRWK=
HAL-01	NVv6WYtoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTF{Lk[xO\|Qh\|ryP	MU\TRW5ITVJ?
NCI-H2141	NGW1[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmmwTWM2OD1zMj62OVgh\|ryP	MnG5V2FPT0WU
HCC1806	MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzNcGlKSzVyPUGyMlY6PTJizszN	MWfTRW5ITVJ?
LU-134-A	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTF{LkmzJO69VQ>?	NW\sXW5QW0GQR1XS
HT	MoG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7JTWM2OD1zMj65OFM4KM7:TR?=	NWHheHBZW0GQR1XS
OE33	NXT4N3Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTxTWM2OD1zMj65OFU3KM7:TR?=	NYf5SZpoW0GQR1XS
ES4	MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXhTWM2OD1zMj65OFg4KM7:TR?=	MkLsV2FPT0WU
SW948	Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTF\|LkCxN{DPxE1?	MnHHV2FPT0WU
LB2241-RCC	M1PxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTF\|LkG0Olkh\|ryP	MWTTRW5ITVJ?
CCF-STTG1	M3HVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjqbI96UUN3ME2xN{41ODN7IN88US=>	NYe3dHloW0GQR1XS
RPMI-8402	MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTF\|LkWwN\|Eh\|ryP	MmC4V2FPT0WU
DEL	M1PO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGr2NI9KSzVyPUGzMlU2ODNizszN	M1W2XHNCVkeHUh?=
NB5	NIO4TFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrEcZVKSzVyPUGzMlU2ODNizszN	M2\JcXNCVkeHUh?=
NUGC-3	NYXJN4pIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DkNWlEPTB;MUOuO\|Q2OyEQvF2=	M3zuTHNCVkeHUh?=
CAL-72	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDOTWM2OD1zND6xPVA3KM7:TR?=	MXLTRW5ITVJ?
VMRC-RCZ	NI\OTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnuTWM2OD1zND6yN\|Yh\|ryP	M4DDUnNCVkeHUh?=
YAPC	NFO1OVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\pV\|ZvUUN3ME2xOE4zPDB5IN88US=>	MVLTRW5ITVJ?
ES5	NIjQSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;2bllzUUN3ME2xOE4zPTl7IN88US=>	MYLTRW5ITVJ?
CAL-12T	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jse2lEPTB;MUSuOFM{PiEQvF2=	MWLTRW5ITVJ?
GAMG	NX3uSnNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PtTmlEPTB;MUSuOVU4PyEQvF2=	NIPLNGVUSU6JRWK=
BT-20	NFnCNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXQcJVKSzVyPUG0Mlk{QDRizszN	MXjTRW5ITVJ?
KALS-1	MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TyTWlEPTB;MUWuNFE2QCEQvF2=	MULTRW5ITVJ?
LS-123	NUjZUZJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fP[mlEPTB;MUWuNFE3PSEQvF2=	NIHyPG1USU6JRWK=
LK-2	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zjUGlEPTB;MUWuNFg3OiEQvF2=	NH[3ZmdUSU6JRWK=
NCI-H1770	NV7MVoV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHYNoR3UUN3ME2xOU4zQDZ6IN88US=>	MWXTRW5ITVJ?
MIA-PaCa-2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfqSY1KSzVyPUG1MlQyPjNizszN	MnTYV2FPT0WU
DB	MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmj0TWM2OD1zNT62PVQyKM7:TR?=	M3jwRnNCVkeHUh?=
Becker	NH7hdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknrTWM2OD1zNT64PVI3KM7:TR?=	NVPa[2ZxW0GQR1XS
HT-144	NWXDWo9MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPNW5RKSzVyPUG1Mlk1QTdizszN	MmLHV2FPT0WU
NCI-H2405	NEHkWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4SyW2lEPTB;MU[uNlIyQCEQvF2=	MX7TRW5ITVJ?
TK10	NIq4ToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PHUGlEPTB;MU[uN\|c1OiEQvF2=	MX7TRW5ITVJ?
THP-1	M4f6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGj2Um5KSzVyPUG2MlQ3PjVizszN	MmT6V2FPT0WU
LB373-MEL-D	M4DQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjUNm1nUUN3ME2xOk43OTN6IN88US=>	NFjke5hUSU6JRWK=
SJSA-1	NUWyS\|lwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTOTWM2OD1zNj65NlE6KM7:TR?=	MVnTRW5ITVJ?
EB2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fqNWlEPTB;MUeuO\|QzPiEQvF2=	NF32OYNUSU6JRWK=
MN-60	NYPzOZVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX70RZBvUUN3ME2xO{44QTN4IN88US=>	MUTTRW5ITVJ?
A253	NGrtUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHBbJJ6UUN3ME2xO{45OjVizszN	NHz0VGdUSU6JRWK=
CESS	MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTF5LkmzNlYh\|ryP	NHTqfZdUSU6JRWK=
EW-11	M3;jOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDodoRxUUN3ME2xO{46QTV6IN88US=>	NYPaV3g1W0GQR1XS
TE-8	M2TOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjLTG5vUUN3ME2xPE4xPjZ7IN88US=>	NV\kSm1JW0GQR1XS
UACC-257	M2e0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;zSmdKSzVyPUG4MlIxPjJizszN	NEDXNG5USU6JRWK=
NCI-H226	NGXUUWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\Wd41KSzVyPUG4MlgzQTlizszN	NYXxSmw1W0GQR1XS
NCI-H748	NUjNfpFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTF6Lki1PFUh\|ryP	NVrBU\|VZW0GQR1XS
NCI-H1299	MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH72dWNKSzVyPUG4Mlg6OThizszN	M2nLVnNCVkeHUh?=
IST-MEL1	NWm3U20zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3[wcGlEPTB;MUmuNVc2PCEQvF2=	M2CxUnNCVkeHUh?=
HCC1187	M1WyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfSTWM2OD1zOT6xO\|k3KM7:TR?=	NEHJTIRUSU6JRWK=
HT-1376	NIHIcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTF7LkKwNlkh\|ryP	NX;yWGp1W0GQR1XS
SK-MEL-2	M3HLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7Zb29KSzVyPUG5MlIyPTVizszN	NFLzPFFUSU6JRWK=
U031	NHOy[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzFXYVKSzVyPUG5MlIzOTlizszN	NWPHe5pmW0GQR1XS
NCI-H524	NHvySGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTF7LkW3NlUh\|ryP	NIPZV\|JUSU6JRWK=
KU812	MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTF7LkW5OFQh\|ryP	MljOV2FPT0WU
NB10	NHTkN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3NTWM2OD1zOT62NlY5KM7:TR?=	M2e4SXNCVkeHUh?=
NOS-1	NYT4Z\|hJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\IWZBJUUN3ME2yNE4yPTd5IN88US=>	M2XsXHNCVkeHUh?=
EW-7	M2XWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTJyLkG2Nlgh\|ryP	NVXJd49CW0GQR1XS
Raji	MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTJyLkK1Olgh\|ryP	MkPlV2FPT0WU
LB2518-MEL	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1T3XmlEPTB;MkCuN\|k2OyEQvF2=	M{TiW3NCVkeHUh?=
PANC-10-05	NYflOZVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M336OWlEPTB;MkCuOFYyOyEQvF2=	MWDTRW5ITVJ?
MZ2-MEL	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWOwS2x2UUN3ME2yNE42QDF2IN88US=>	MX;TRW5ITVJ?
MFE-280	NH;OV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXnTWM2OD1{MT6zNVg5KM7:TR?=	M3f5eHNCVkeHUh?=
RKO	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2roUWlEPTB;MkGuN\|IxOiEQvF2=	M3;aZ3NCVkeHUh?=
KMOE-2	M1zJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVz1UWIxUUN3ME2yNU4{Ojh6IN88US=>	MXrTRW5ITVJ?
K5	NYLPZ5RnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DnRmlEPTB;MkGuN\|g6OyEQvF2=	M{j1XHNCVkeHUh?=
NCI-H64	NHrBR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTJzLkS3OVYh\|ryP	NFqzcndUSU6JRWK=
K-562	M3uxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\DbYJuUUN3ME2yNU41QTdzIN88US=>	MnHMV2FPT0WU
HCE-T	M3TIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXlNlJjUUN3ME2yNU42ODl2IN88US=>	M3zLe3NCVkeHUh?=
COLO-792	MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXYSZc4UUN3ME2yNU42QDJ5IN88US=>	MYPTRW5ITVJ?
PFSK-1	NG\IVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHW3WHBKSzVyPUKxMlY5OzdizszN	MmjtV2FPT0WU
DOK	Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTJzLke2PFch\|ryP	M37xNXNCVkeHUh?=
NCI-H1882	M3T2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTJzLki1PVYh\|ryP	MV3TRW5ITVJ?
KNS-81-FD	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTJzLki2N\|Eh\|ryP	M4rzN3NCVkeHUh?=
OCUB-M	M{XvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\CXnF1UUN3ME2yNU46Pjh6IN88US=>	M{S4fXNCVkeHUh?=
NCI-H1694	M4nQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NID5c2tKSzVyPUKxMlk5PjNizszN	M1u3cXNCVkeHUh?=
LS-513	MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzJUXZKSzVyPUKyMlA{PjdizszN	MVrTRW5ITVJ?
NCI-H2122	MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTJ{LkG2O\|ch\|ryP	NELiNVRUSU6JRWK=
IMR-5	NV;lfo91T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzGd\|MyUUN3ME2yNk4zQDdizszN	M{LBVnNCVkeHUh?=
SNU-C2B	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnpTWM2OD1{Mj62O\|Q3KM7:TR?=	MlnxV2FPT0WU
A498	NF3Bc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3xVFhKSzVyPUKyMlgyPzdizszN	NVLOOWFUW0GQR1XS
NCI-H727	NHTuUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjofWJKSzVyPUKyMlg5OzZizszN	MX\TRW5ITVJ?
SW1573	MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTJ\|LkC2OFYh\|ryP	M{PoTnNCVkeHUh?=
RO82-W-1	NHTsNHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTJ\|LkK1NVEh\|ryP	NIn5fG9USU6JRWK=
SKG-IIIa	MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7kdJRKSzVyPUKzMlM2PDZizszN	M2[1cXNCVkeHUh?=
MC-CAR	M4T2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1[4W2lEPTB;MkOuOVE5OyEQvF2=	MV\TRW5ITVJ?
NCI-H446	MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\pfG5bUUN3ME2yN{43ODl\|IN88US=>	NXfZfYtiW0GQR1XS
PC-14	MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGf2dFBKSzVyPUKzMlY3OjNizszN	M3XX[XNCVkeHUh?=
TGBC1TKB	NF:4Z5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTaOHZ4UUN3ME2yN{44PDZzIN88US=>	Mkj3V2FPT0WU
EFM-19	M3nWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEOzcGZKSzVyPUK0MlE5PDRizszN	M{\GfXNCVkeHUh?=
SK-N-DZ	M4DOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfGeW1KSzVyPUK0MlQ6PzdizszN	NXHFNmloW0GQR1XS
NCI-H661	M1PDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{iwOGlEPTB;MkSuOVIyPyEQvF2=	NWXvR\|A2W0GQR1XS
SW1990	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfKO4ZKSzVyPUK0MlU5QDNizszN	NF:1R49USU6JRWK=
SW684	MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIX4UIxKSzVyPUK0Mlc3OjRizszN	NVL5NWo3W0GQR1XS
Ca-Ski	NYrZWWV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TNe2lEPTB;MkSuPVI{PyEQvF2=	NX;BbmpYW0GQR1XS
TGW	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkn0TWM2OD1{NT6yN\|M4KM7:TR?=	MYLTRW5ITVJ?
CaR-1	MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTXdI06UUN3ME2yOU4{PTdizszN	MnvHV2FPT0WU
D-247MG	NWXGU3RMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\NTWM2OD1{NT60O\|Q{KM7:TR?=	NIHZRpdUSU6JRWK=
CCRF-CEM	M3fn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nhfWlEPTB;MkWuO\|Q2QSEQvF2=	NFrueXNUSU6JRWK=
CAPAN-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXi0bGpCUUN3ME2yOU44PTBzIN88US=>	NYHwfHF1W0GQR1XS
CP50-MEL-B	M2rHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYCxO2RHUUN3ME2yOU46QTBzIN88US=>	NEjlbGFUSU6JRWK=
FADU	NH;2emRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTy[ZVVUUN3ME2yOk42OTV{IN88US=>	NIPqT\|FUSU6JRWK=
Daudi	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmiwTWM2OD1{Nj61NVU5KM7:TR?=	MWLTRW5ITVJ?
U-87-MG	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTJ4LkWzNFUh\|ryP	Mn3rV2FPT0WU
DSH1	MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHvfZZRUUN3ME2yOk42PDB4IN88US=>	M3rWSnNCVkeHUh?=
KYSE-520	M4TXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnxTWM2OD1{Nj61OVU{KM7:TR?=	NXXqTJk6W0GQR1XS
HuH-7	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTJ4LkmwPFYh\|ryP	NWDj[4hjW0GQR1XS
U-2-OS	NIXVe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkj2TWM2OD1{Nz6wNlcyKM7:TR?=	M37Kb3NCVkeHUh?=
LU-99A	M4XFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWW0U2t3UUN3ME2yO{4yPzV2IN88US=>	M33JVHNCVkeHUh?=
T98G	MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTkTWM2OD1{Nz6xPVc{KM7:TR?=	M3K1W3NCVkeHUh?=
MZ7-mel	NH\rb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfaTWM2OD1{Nz61OVQ5KM7:TR?=	MWTTRW5ITVJ?
SNU-C1	NUDpcYJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPpOYtxUUN3ME2yO{43PDlzIN88US=>	M1OzZ3NCVkeHUh?=
MDA-MB-175-VII	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTJ5Lk[5O\|Uh\|ryP	MXrTRW5ITVJ?
HuP-T3	NGDvdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HUc2lEPTB;MkiuNFQ6PSEQvF2=	NITVNHdUSU6JRWK=
T-24	MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHW4TndKSzVyPUK4MlE6OjVizszN	M3HpXHNCVkeHUh?=
HDLM-2	M1[0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3ObYQ6UUN3ME2yPE4zPDV7IN88US=>	M{HTdnNCVkeHUh?=
NCI-H1651	MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\aTVNKSzVyPUK4MlI2QTJizszN	NITHRo1USU6JRWK=
SK-N-AS	NEfJSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrXe2RVUUN3ME2yPE4{OTdzIN88US=>	NV;Ne\|VGW0GQR1XS
NY	NFPEWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{ThOWlEPTB;MkiuOlU4QSEQvF2=	MlLTV2FPT0WU
D-283MED	Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDZTWM2OD1{OD64O\|A5KM7:TR?=	MYLTRW5ITVJ?
KLE	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXYTWM2OD1{OD65PVA3KM7:TR?=	NUPqSZVUW0GQR1XS
NCI-H28	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkexTWM2OD1{OT6wNVIh\|ryP	NW\hS2VDW0GQR1XS
TE-1	MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfuNWF6UUN3ME2yPU4zOTZ5IN88US=>	NHXyR2JUSU6JRWK=
SK-MEL-24	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPnUWRXUUN3ME2yPU42PDZ4IN88US=>	NELQUnRUSU6JRWK=
CAL-54	NWXubIJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTJ7Lk[wOFYh\|ryP	NFLLbFVUSU6JRWK=
A673	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XINGlEPTB;MkmuO\|MzKM7:TR?=	M3Ox[XNCVkeHUh?=
HEC-1	NHe4VVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHGRnprUUN3ME2zNE4xODV\|IN88US=>	MW\TRW5ITVJ?
LS-411N	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnpWGFbUUN3ME2zNE4yPDd3IN88US=>	MVnTRW5ITVJ?
SW962	M3XibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTNyLkK0O\|ch\|ryP	NXzzN5BIW0GQR1XS
OVCAR-8	NGfyTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjhbYlKSzVyPUOwMlY4QTRizszN	NUfvWo1xW0GQR1XS
NCI-H630	M2n4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHv3WJlKSzVyPUOwMlg6PTNizszN	NWDRVGNtW0GQR1XS
D-263MG	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XlUWlEPTB;M{GuNFQzPCEQvF2=	Mm\PV2FPT0WU
NCI-H596	NYjNSZhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTNzLkC2NlEh\|ryP	NWHhbnVyW0GQR1XS
BB49-HNC	MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jQeWlEPTB;M{GuNVEzKM7:TR?=	NEjKOGJUSU6JRWK=
KYSE-70	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7XTVNKSzVyPUOxMlMxODhizszN	NVjaSFl2W0GQR1XS
LAN-6	NYPsXXIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjIRVAzUUN3ME2zNU41QTl{IN88US=>	M{Owb3NCVkeHUh?=
NCI-H2228	M3\HSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1v2fGlEPTB;M{GuOVYzPSEQvF2=	NVLzc2YyW0GQR1XS
SW620	NGDycHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrlUHl3UUN3ME2zNU43Ojh\|IN88US=>	MYjTRW5ITVJ?
KM-H2	M1\ONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIW1XFRKSzVyPUOxMlc{ODZizszN	MXXTRW5ITVJ?
DJM-1	NVHpVoZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTN{LkGzPFYh\|ryP	MW\TRW5ITVJ?
SW48	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HmO2lEPTB;M{KuN\|gzPSEQvF2=	M{nzfnNCVkeHUh?=
NCI-H1793	NVW5e3ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDSOmlUUUN3ME2zNk43OTZ\|IN88US=>	NXT5flVyW0GQR1XS
LU-165	M4LUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTN\|LkCwPEDPxE1?	NGLDe4JUSU6JRWK=
EHEB	M3HoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1X6VmlEPTB;M{OuNFQ6PCEQvF2=	MVXTRW5ITVJ?
NCI-H441	M33YOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\NZWlEPTB;M{OuNlI{PSEQvF2=	NFexTJFUSU6JRWK=
LOXIMVI	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTN\|LkO2O\|kh\|ryP	NGDBPVVUSU6JRWK=
MC-IXC	NEHBfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2H6N2lEPTB;M{OuOVY2PSEQvF2=	NHvjNG5USU6JRWK=
NCI-H522	NH\uZ\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTN\|Lk[1OEDPxE1?	MVzTRW5ITVJ?
IA-LM	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDZT\|A2UUN3ME2zN{43PzR4IN88US=>	NGDZdFJUSU6JRWK=
NCI-H1417	Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXwXGRKSzVyPUOzMlk2QDVizszN	NILtbHdUSU6JRWK=
HCC2218	NG\RSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33OTmlEPTB;M{WuNlE5PSEQvF2=	NXzOS\|VrW0GQR1XS
HC-1	NHSxWmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13VWWlEPTB;M{WuOFAzPCEQvF2=	M3LUNXNCVkeHUh?=
HH	NEnDblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX76dGVYUUN3ME2zOU41OTRzIN88US=>	MnHNV2FPT0WU
EFE-184	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDLTWM2OD1\|NT62PFI6KM7:TR?=	MYnTRW5ITVJ?
NCI-H1355	MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rETmlEPTB;M{WuO\|cyQCEQvF2=	M{HCWHNCVkeHUh?=
BV-173	MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1ryWWlEPTB;M{WuPFI3PCEQvF2=	NXnuepgzW0GQR1XS
NEC8	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnnPYNKSzVyPUO2MlQ6OjRizszN	M{jSO3NCVkeHUh?=
SW1463	NYOyN4VmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkmzTWM2OD1\|Nj62OVY3KM7:TR?=	MYPTRW5ITVJ?
KYSE-140	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\hRWZKSzVyPUO2MlczQThizszN	NX\BclY{W0GQR1XS
no-11	M3TaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTNTWM2OD1\|Nj64OVM3KM7:TR?=	NHXN[FBUSU6JRWK=
HCC1937	MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moi3TWM2OD1\|Nz6wNVU1KM7:TR?=	M3W4bnNCVkeHUh?=
LNCaP-Clone-FGC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTN5LkG5NFMh\|ryP	NEXQPWVUSU6JRWK=
KARPAS-422	M2n4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHrTWM2OD1\|Nz60OFMyKM7:TR?=	NYX2W2ZnW0GQR1XS
RCM-1	NWnqWXJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDxc5pKSzVyPUO3MlU{PThizszN	NEnNepFUSU6JRWK=
A375	NGLhWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rZVGlEPTB;M{euO\|Y1PyEQvF2=	MV3TRW5ITVJ?
TGBC24TKB	NYjJTVg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWWzOJg6UUN3ME2zPE4xOjN7IN88US=>	M{XCfnNCVkeHUh?=
MDA-MB-453	NFzIUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoGyTWM2OD1\|OT6wNlE5KM7:TR?=	NH;k[GxUSU6JRWK=
Capan-2	NWniTHQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoGxTWM2OD1\|OT6wOVA6KM7:TR?=	NUTpRXJTW0GQR1XS
SW756	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzZelVKSzVyPUO5MlUxQTFizszN	MofVV2FPT0WU
KU-19-19	NG\2doRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXxZXVKSzVyPUO5MlYzQDJizszN	MkXjV2FPT0WU
NCI-H2170	M1qwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{e4OGlEPTB;M{muPVk4PyEQvF2=	NWO5c2hRW0GQR1XS
COLO-678	Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvXTWM2OD12MD61PVUh\|ryP	NGrXOWFUSU6JRWK=
PF-382	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTRyLke0PFch\|ryP	NECxc3VUSU6JRWK=
OAW-42	MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fzSmlEPTB;NEKuNlk1OiEQvF2=	NEn6fotUSU6JRWK=
LB996-RCC	MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjNfmxKSzVyPUSyMlgxODhizszN	MkT5V2FPT0WU
SAS	M{Tkd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHhNG83UUN3ME20N{41Ojh6IN88US=>	NYC0cIR[W0GQR1XS
MRK-nu-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIL0Ro1KSzVyPUS0Mlc1OTRizszN	NXLSUIM{W0GQR1XS
EoL-1-cell	NYrFNJV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDxTWM2OD12ND65NVM3KM7:TR?=	MYXTRW5ITVJ?
NCI-H2342	M{fwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLldoFKSzVyPUS1MlEyOTdizszN	MX;TRW5ITVJ?
NCI-H1703	MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3SdllKSzVyPUS2MlA2QTJizszN	NInDSZNUSU6JRWK=
NCI-H187	M1Ptd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXoco9KSzVyPUS2MlE5PjlizszN	NH35U\|lUSU6JRWK=
CP66-MEL	M4Xldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTR4LkK3PFkh\|ryP	M3zVeHNCVkeHUh?=
HCC1569	NFPlWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHu0cHRKSzVyPUS2MlU6OTdizszN	NVzTTW44W0GQR1XS
BL-70	M1jwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHyUHNUUUN3ME20Ok44PzN5IN88US=>	M1LBbnNCVkeHUh?=
Saos-2	NV;Cb\|BtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3:3fmlEPTB;NEeuN\|EzOyEQvF2=	MYXTRW5ITVJ?
LC-1F	NGfGboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTs[4FKSzVyPUS3MlYyODVizszN	MX7TRW5ITVJ?
KY821	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\ZSmlEPTB;NEeuOlQ{PCEQvF2=	NYrEWVlKW0GQR1XS
PSN1	M2XTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHn4bIZKSzVyPUS4MlE1ODFizszN	MofmV2FPT0WU
RT4	M2[1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoOzTWM2OD12OD64N\|c4KM7:TR?=	MkPDV2FPT0WU
LS-1034	NWGyNYxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFuwcndKSzVyPUS4Mlg6PTRizszN	M2rUUnNCVkeHUh?=
NCI-H1395	NWPRSZRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTR7LkC0PVIh\|ryP	MVTTRW5ITVJ?
EKVX	NYXD[Jk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWT3PIpNUUN3ME20PU43PzNzIN88US=>	MlfTV2FPT0WU
IST-MES1	NGXGNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7mUVRKSzVyPUS5Mlg6PDRizszN	MXvTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-FAK / FAK / p-Talin / Talin ; PubMed: 26530902 Cancer Res Dose response of PF-562271 on the phosphorylation of FAK-Y397 or Talin-S425 in PC3-mm2 cells. p-Src / Src / p-paxillin / Paxillin / ICAM-1 ; PubMed: 29417941 Acta Pharmacol Sin MDA-MB-231 cells transfected with FAK-specific siRNAs or treated for 12 h with PF-562271 at the indicated concentrations were subjected to immunoblotting with indicated antibodies.	26530902 29417941
Immunofluorescence	p-FAK; PubMed: 26530902 Cancer Res Immunostaining of PC3-mm2 cells showed that phosphorylated FAK is localized at focal adhesions (inset).	26530902
Growth inhibition assay	Cell viability; PubMed: 28953264 Nutrients MTT assay showed inhibition of cell proliferation and viability in HCT116 (B) and SW480 (D) cell lines treated with resveratrol and/or different concentrations of FAK-Inhibitor (PF-562271: 0.01, 0.1, 1, and 10 µM) cultured in monolayer for 12 h. Data shown are representative of three independent sets of experiments. Values were compared with the control and statistically significant values with p < 0.05 are designated by an asterisk () and p < 0.01 are designated by two asterisks (*).	28953264

In vivo

PF-562271 (< 33 mg/kg p.o.) inhibits FAK phosphorylation in tumors in a dose- and time-dependent manner in U87MG-bearing mice. PF-562271 (50 mg/kg p.o. bid) results in 86% tumor growth inhibition in BxPc3 xenografts mice and 45% tumor growth inhibition in PC3-M xenografts mice. PF-562271 (25 mg/kg, bid) results in 2-fold greater apoptosis in treated tumors in mice bearing H125 lung xenografts. ^[1] PF-562271 (33 mg/kg, p.o.) inhibits extensive movement of the tumor cells over 24 hours in mice. PF-562271 (33 mg/kg, p.o.) results in altered E-cadherin dynamics in mice, which correlates with reduced E-cadherin–dependent collective cell movement. ^[3] PF-562271 (25 mg/kg, p.o. bid) results in 62% tumor growth inhibition in PC3M-luc-C6 subcutaneuous local implant xenograft mouse model. ^[4] PF-562,271 (5 mg/kg, oral) results in significant and similar increases in osteocalcin and cancellous bone parameters and a decrease in tumor growth and signs of bone healing in rats implanted with MDA-MB-231 cells in the tibia. ^[5]

Protocol

Animal Research:^[1]	- Collapse Animal Models: Athymic female mice bearing BxPc3 or PC3-M xenografts. Formulation: 5% Gelucire Dosages: 50 mg/kg Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL warmed (197.04 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O For best results, use promptly after mixing.	5 mg/ml

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-562271 SDF

Molecular Weight	507.49
Formula	C₂₁H₂₀F₃N₇O₃S
CAS No.	717907-75-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

FAK Signaling Pathway Map

Related FAK Products

PND-1186 (VS-4718) ^New

PND-1186 (VS-4718) is a reversible and selective FAK inhibitor with IC50 of 1.5 nM. Phase 1.
PF-431396 ^New

PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively.
Defactinib (VS-6063, PF-04554878) ^New

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
PF-00562271 Besylate

PF-00562271 Besylate is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
TAE226 (NVP-TAE226)

TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met.
PF-573228

PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-free assay, ~50- to 250-fold selective for FAK than Pyk2, CDK1/7 and GSK-3β.
PF-562271 HCl

PF-562271 HCl is the hydrochloride salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.
Dasatinib

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-562271

Cited by 66 Publications

Purity & Quality Control

Choose Selective FAK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PF-562271 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

FAK Signaling Pathway Map

Related FAK Products

Choose Your Country or Region

By Signaling Pathways

By product type

PF-562271

Cited by 66 Publications

Purity & Quality Control

Choose Selective FAK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PF-562271 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

FAK Signaling Pathway Map

Related FAK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)